Otsuka Holdings Co., Ltd.: Neoplasms trials

The registry lists 21 Neoplasms studies with Otsuka Holdings Co., Ltd. as lead sponsor. 1 are open to participants now and 3 have results posted.

Phase 1 21Phase 2 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of ARC-02 in B-cell NHLRecruitingNCT07691606Phase 1
• Study of ASTX029 in Subjects With Advanced Solid TumorsCompletedNCT03520075Phase 1/2Results posted
• A Phase I Study of TAS-102 in Solid TumorsCompletedNCT02261532Phase 1Results posted
• A Study of TAS-120 in Patients With Advanced Solid TumorsCompletedNCT02052778Phase 1/2Results posted
• TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN MutationsTerminatedNCT04770246Phase 1
• A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid NeoplasmsTerminatedNCT04637009Phase 1
• A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor CancerTerminatedNCT04586270Phase 1
• Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53TerminatedNCT03975387Phase 1
• A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 AbnormalitiesTerminatedNCT03410927Phase 1
• A Study of TAS-116 in Patients With Solid TumorsCompletedNCT02965885Phase 1
• A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic ImpairmentCompletedNCT02301104Phase 1
• Safety and Biomarker of OPB-111077 in Subjects With Advanced Solid TumorCompletedNCT02250170Phase 1
• Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid TumorsTerminatedNCT02134067Phase 1
• Study of the Mass Balance of Oral FTD and TPI as Components of TAS-102 in Patients With Advanced Solid TumorsCompletedNCT02031055Phase 1
• Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid TumorsCompletedNCT01867879Phase 1
• A Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid TumorsCompletedNCT01610479Phase 1
• Phase 1, Open-label Trial to Determine Safety of OPB-51602 in Subjects With Advanced CancerCompletedNCT01423903Phase 1
• Phase 1, Dose-escalation Trial of OPB-51602 in Patients With Advanced Solid TumorsCompletedNCT01184807Phase 1
• Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid MalignanciesCompletedNCT00894894Phase 1
• Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid TumorsCompletedNCT00878423Phase 1
• An Open-Label Phase-1 Study of OPB-31121 in Patients With Advanced Solid TumorsStatus unknownNCT00657176Phase 1